Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-8 of 8 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-8 of 8 studies
-
Anti-InfectiveClosed to Enrollment
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study , protocol number Novartis CTBM100C2401E1The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 75%
-
Number of Visits:
8
-
Length of Participation:
48 weeks
-
-
Anti-InfectiveCompleted with Results
Tobramycin Inhalation Powder Compared to TOBI in People with CF , protocol number CTBM100C2302-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 75%
-
Number of Visits:
11
-
Length of Participation:
6 months
-
-
Anti-InfectiveCompleted with Results
Inhaled Fosfomycin/Tobramycin for People with CF and P. aeruginosa , protocol number Gilead GS-US-207-0103The purpose of this study is to evaluate the safety and efficacy of 2 dose combinations of fosfomycin/tobramycin for inhalation (FTI), following a 28-day course of Aztreonam for Inhalation (AZLI) in patients with cystic fibrosis and Pseudomonas aeruginosa lung infection.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 75%
-
Number of Visits:
7
-
Length of Participation:
14 weeks
-
-
Anti-InfectiveCompleted with Results
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered Twice a Day Cycled , protocol number NOVARTIS CTBM100CUS03This open-label study tested the effectiveness and safety of two different dose regimens of Tobramycin Inhalation Powder (TIP) for the treatment of Pseudomonas aeruginosa.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 80%
-
Number of Visits:
9
-
Length of Participation:
24 weeks
-
-
Anti-InfectiveCompleted with Results
OPTIMIZE: Phase 3 study of tobramycin solution for inhalation with and without azithromycin , protocol number OPTIMIZE-IP-12This study evaluated the effect of treatment with tobramycin inhalation solution (TIS) with and without azithromycin in people with CF who had their first isolation of Pseudomonas aeruginosa (Pa) from a respiratory culture (or their first culture after being negative for Pa for at least 2 years).
-
Age:
6 Months to 18 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
18 months
-
-
Anti-InfectiveCompleted with Results
Aztreonam for Inhalation Solution (AZLI) taken in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas aeruginosa lung infections in people with CF , protocol number Gilead GS-US-205-0170This study evaluated if continuous alternating treatment with two different types of inhaled antibiotics [Aztreonam for Inhalation Solution (Cayston®) and Tobramycin Inhalation Solution (TIS)] , resulted in better outcomes than an intermittent regimen (28 days on/28 days off) of TIS.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 75%
-
Number of Visits:
9
-
Length of Participation:
7 months
-
-
Anti-InfectiveCompleted with Results
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis , protocol number Novartis CTBM100C2401This open-label study assessed the long term safety of tobramycin inhalation powder (TIP) in people with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 75%
-
Number of Visits:
9
-
Length of Participation:
52 weeks
-
-
Anti-InfectiveCompleted with Results
Levofloxacin Inhalation Solution (Aeroquin™) compared to TOBI® in people with Cystic Fibrosis , protocol number MPEX 209This study looked at the safety and effectiveness of levofloxacin inhalation solution (AEROQUIN™), compared to tobramycin solution for inhalation (TIS in people with CF who had chronic Pseudomonas aeruginosa lung infection.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 85%
-
Number of Visits:
10
-
Length of Participation:
6 months
-
Showing 1-8 of 8 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More